IntelGenx Technologies (OTCMKTS:IGXT) has been given a $2.00 price objective by stock analysts at HC Wainwright in a research note issued to investors on Wednesday. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 193.17% from the stock’s current price.

Separately, ValuEngine cut IntelGenx Technologies from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd.

Shares of IntelGenx Technologies (OTCMKTS IGXT) remained flat at $$0.68 during mid-day trading on Wednesday. 45,642 shares of the stock traded hands, compared to its average volume of 77,336. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.65 and a quick ratio of 2.65. IntelGenx Technologies has a one year low of $0.62 and a one year high of $1.09.

TRADEMARK VIOLATION NOTICE: “HC Wainwright Analysts Give IntelGenx Technologies (IGXT) a $2.00 Price Target” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/12/06/hc-wainwright-analysts-give-intelgenx-technologies-igxt-a-2-00-price-target.html.

IntelGenx Technologies Company Profile

IntelGenx Technologies Corp. is a drug delivery company focusing on the development of orally administered drug delivery products based on its oral drug delivery technologies. The Company is a provider of product development services for the pharmaceutical industry, including the branded and generic pharmaceutical markets.

Receive News & Ratings for IntelGenx Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelGenx Technologies Corp. and related companies with MarketBeat.com's FREE daily email newsletter.